Start with the old limitation and the perspective changed by the research, then follow evidence-backed company links and later patents, products, contracts, production, and clinical changes.
Last data check 2026-10-07 00:30 UTC
Publication and SciSignal discovery dates are separated, with what changed shown first.
This study evaluated the effect of temporarily stopping biologic or targeted synthetic DMARD therapy on the immune response to a COVID-19 supplemental dose vaccine and on disease activity in patients with inflammatory arthritis.
The study demonstrates that engineering bonding sites enhances the uniformity and stability of self-assembled monolayers for perovskite solar cells.
The study presents a process for rapidly testing the effectiveness of personalized nucleic acid therapies in heart organoids derived from patient cells.
The study systematically identified gene edits that enhance the cancer-fighting ability and survival of CAR-T cells.
The study demonstrates a rechargeable all-solid-state hydride ion battery that operates at room temperature.
The study demonstrates real-time in situ magnetization reprogramming for soft robotics, enabling dynamic changes in magnetic patterns to achieve different movements and functions.
This study uses deep networks to infer Jacobian fields for controlling diverse robots without prior modeling of their structure.
The study demonstrates scalable production of human cortical organoids using a biocompatible polymer to reduce aggregation.
Only companies supported by research participation or official evidence appear.
When there is no new company event, recently rechecked source status is shown.
Continue through fields that already contain real public technology.
Explore technical potential without forcing a company connection.